Synthesis and serotonin receptor activity of the arylpiperazine alkyl/propoxy derivatives of new azatricycloundecanes

European Journal of Medicinal Chemistry

Volumn 44, Issue 1, 2009, Pages 152-164

  Bojarski, A J ^a   Kuran, B ^b   Kossakowski, J ^b   Koziol A ^a   Jagiello Wojtowicz E ^c   Chodkowska, A ^c  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

5 HT1A receptor; 5 HT2A receptor; Antidepressant activity; Arylpiperazine; Azatricycloundecane; Fujita Ban analysis

Indexed keywords

4 [3 [4 (2 FLUOROPHENYL)PIPERAZIN 1 YL]PROPOXY] 8,11 DIMETHYL 3,5 DIOXO 4 AZATRICYCLO[5.2.2.0 2,6]UNDEC 8 EN 1 YL ACETATE; 4 [3 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]PROPOXY] 1,11 DIMETHYL 4 AZATRICYCLO[5.2.2.0 2,6]UNDEC 3,5,8 TRIONE; 4 [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL] 8,11 DIMETHYL 3,5 DIOXO 4 AZATRICYCLO[5.2.2.0 2,6]UNDEC 8 EN 1 YL ACETATE; IMIPRAMINE; PIPERAZINE DERIVATIVE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FORCED SWIMMING TEST; MOUSE; NONHUMAN; PREDICTION; RECEPTOR AFFINITY;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANXIETY; DEPRESSION; MICE; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57949099040     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.03.019     Document Type: Article

References (22)

1. Den Boer J.A., Bosker F.J., and Slaap B.R. Hum. Psychopharmacol. 15 (2000) 315-336
2. Hoyer D., Hannon J.P., and Martin G.R. Pharmacol. Biochem. Behav. 71 (2002) 533-554
3. Celada P., Puig M., Amargos-Bosch M., Adell A., and Artigas F. J. Psychiatry Neurosci. 29 (2004) 252-265
4. Fulton B., and Brogden R.N. CNS Drugs 7 (1997) 68-88
5. Marek G.J., Carpenter L.L., McDougle C.J., and Price L.H. Neuropsychopharmacology 28 (2003) 402-412
6. Kossakowski J., and Jarocka M. Farmaco 56 (2001) 785-789
7. Kossakowski J., and Krawiecka M. Acta Pol. Pharm. 60 (2003) 177-182
8. Kossakowski J., and Hejchman E. Acta Pol. Pharm. 60 (2003) 61-66
9. Berardi F., Colabufo N.A., Giudice G., Perrone R., Tortorella V., Govoni S., and Lucchi L. J. Med. Chem. 39 (1996) 176-182
10. Costantino L., Gandolfi F., Sorbi C., Franchini S., Prezzavento O., Vittorio F., Ronsisvalle G., Leonardi A., Poggesi E., and Brasili L. J. Med. Chem. 48 (2005) 266-273
11. Fujita T., and Ban T. J. Med. Chem. 14 (1971) 148-152
12. Boissier J.R., Tardy J., and Diverres J.C. Med. Exp. 3 (1960) 81-84
13. Aron C., Simon P., Larousse C., and Boissier J.R. Neuropharmacology 10 (1971) 459-469
14. Porsolt R.D., Bertin A., and Jalfre M. Arch. Int. Pharmacodyn. Ther. 229 (1977) 327-336
15. Kubinyi H. Quant. Struct.-Act. Relat. 7 (1988) 121-133
16. Mokrosz J.L., Mokrosz M.J., Charakchieva-Minol S., Paluchowska M.H., Bojarski A.J., and Duszyńska B. Arch. Pharm. (Weinheim) 328 (1995) 143-148
17. Obniska J., Kolaczkowski M., Charakchieva-Minol S., Nedza K., Dybala M., and Bojarski A.J. Pharmacol. Rep. 57 (2005) 336-344
18. Zomkowski A.D.E., Rosa A.O., Lin J., Santos A.R., Calixto J.B., and Rodrigues A.L.S. Brain Res. 1023 (2004) 253-263
19. Matsuno K., Kobayashi T., Tanaka M.K., and Mita S. Eur. J. Pharmacol. 312 (1996) 267-271
20. Chaki S., Hirota S., Funakoshi T., Suzuki Y., Suetake S., Okubo T., Ishii T., Nakazato A., and Okuyama S. J. Pharmacol. Exp. Ther. 304 (2003) 818-826
21. Fieser M., Fieser L.F., and Smith J.G. Reagents for Organic Synthesis (1990) p. 290
22. Bojarski A.J., Cegła M.T., Charakchieva-Minol S., Mokrosz M.J., Maćkowiak M., and Mokrosz J.L. Pharmazie 48 (1993) 289-294